The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Full Resumption of Quake-Hit Santen Plant Delayed into April
Japanese ophthalmology powerhouse Santen Pharmaceutical said on March 11 that its plan to fully resume operations of its plant hit by the Noto Peninsula earthquake will be pushed back into April or later. The company previously said that production lines…
To read the full story
Related Article
- Quake-Hit Santen Plant to Fully Go Back Online in March
February 8, 2024
- Resuming Production at Quake-Hit Plant Will Take Some Time: Santen
January 17, 2024
- Santen Curbs Cosopt Mini Shipments after Quake, Nitto Medic to Re-Supply All Products
January 12, 2024
- Quake Causes Eye Drug Maker to Stop Shipments Except Refrigerated Meds
January 10, 2024
- Santen, Astellas, 3 More Firms Hit by Manufacturing Delays after Quake
January 9, 2024
BUSINESS
- iPark Institute to Launch AI-Based Platform to Link Investors with Startups
January 16, 2026
- Acromegaly Drug Palsonify Meets Primary Endpoint in Japan PII/PIII Trial
January 16, 2026
- Tanabe’s EPP/XLP Drug Hits Main Goals in PIII, Weighs Launch Strategy
January 16, 2026
- Forxiga Generics Reach 11% Share in First Month: Intage
January 16, 2026
- Takeda to Halt Sales of Cell Therapy Alofisel in Japan
January 15, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…